How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

16,387 results for

Breast Cancer Risk Factors

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Risk factors for breast cancer: A review of the evidence 2018

Risk factors for breast cancer: A review of the evidence 2018 Risk factors for breast cancer: A review of the evidence 2018 Breast cancer risk factors: A review of the evidence i Risk factors for breast cancer: A review of the evidence was prepared and produced by: Cancer Australia Locked Bag 3 Strawberry Hills NSW 2012 Australia Tel: +61 2 9357 9400 Fax: +61 2 9357 9477 canceraustralia.gov.au © Cancer Australia 2018. ISBN Print: 978–1–74127–336–6 ISBN Online: 978–1–74127–337–3 Recommended (...) citation Cancer Australia, 2018. Risk factors for breast cancer: A review of the evidence, Cancer Australia, Surry Hills, NSW. Risk factors for breast cancer: A review of the evidence can be downloaded from the Cancer Australia website: canceraustralia.gov.au Copyright statements Internet sites This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within

2018 Cancer Australia

3. Breast Cancer Risk Factors At a Glance

Breast Cancer Risk Factors At a Glance Age 50 years old 30 years old Height 172 cm 162 cm ( average female height in Australia ) Reproductive factors Family history and genetic factors Lifestyle factors Personal factors VS. VS. 152 cm 162 cm ( average female height in Australia ) Mammographic breast density VS. Extremely dense breasts averagely dense breasts VS. Body mass index ( postmenopausal women ) VS. Adult weight gain ( postmenopausal women ) Weight gain (5kg) no weight gain VS. Weight (...) gain (10kg) Weight gain (20kg) Alcohol consumption 2 drinks per day no daily alcohol consumption VS. Physical activity Most active least active ( postmenopausal women ) VS. 4 drinks per day 6 drinks per day Breast Cancer Risk Factors At a Glance Decreased risk Increased risk 1 2 3 4 5 6 7 8 910 0.5 0.33 0.25 0.2 0.125 0.1 10 1.17 0.85 2.14 1.12 1.25 1.40 1.06 1.12 1.26 1.15 1.31 1.50 0.87 VS. VS. no weight gain VS. no weight gain VS. no daily alcohol consumption VS. no daily alcohol consumption VS

2018 Cancer Australia

4. Causes and risk factors: Women with schizophrenia are at increased risk of breast cancer

Causes and risk factors: Women with schizophrenia are at increased risk of breast cancer Women with schizophrenia are at increased risk of breast cancer | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Women with schizophrenia are at increased risk of breast cancer Article Text Commentary Causes and risk factors Women with schizophrenia are at increased risk of breast cancer Alison R Yung 1 , 2 , Joseph Firth 1 , 3 Statistics from

2018 Evidence-Based Mental Health

5. Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study. (PubMed)

Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study. Invasive breast cancers are thought to arise from in situ lesions, but some ductal carcinoma in situ (DCIS) are indolent with low likelihood of progressing to invasive carcinoma. Comparison of risk factor associations between DCIS and invasive disease may elucidate which factors influence early versus late stages of carcinogenesis. Therefore, we determined whether (...) there were differences in risk factor profiles for screen-detected DCIS and invasive breast cancer among Luminal A lesions.We conducted a case-control analysis using data from the Carolina Breast Cancer Study (1993-2001). Analyses were restricted to Luminal A tumors and screen-detected tumors among mammography-eligible women, to limit confounding by mode of detection (N = 108 DCIS; N = 203 invasive). Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI

Full Text available with Trip Pro

2019 PLoS ONE

6. Breast cancer risk factors in relation to estrogen receptor, progesterone receptor, insulin-like growth factor-1 receptor, and Ki67 expression in normal breast tissue (PubMed)

Breast cancer risk factors in relation to estrogen receptor, progesterone receptor, insulin-like growth factor-1 receptor, and Ki67 expression in normal breast tissue Studies have suggested that hormone receptor and Ki67 expression in normal breast tissue are associated with subsequent breast cancer risk. We examined the associations of breast cancer risk factors with estrogen receptor (ER), progesterone receptor (PR), insulin-like growth factor-1 receptor (IGF-1R), and Ki67 expression (...) expression. Body size at age 5-10 years was inversely associated with Ki67 (Level ≥ 2.5 vs. 1: OR = 0.55, 95% CI = 0.30-1.01, p-trend = 0.03). Premenopausal BMI (≥25 vs.<20 kg/m2) was positively associated with cytoplasmic IGF-1R (OR = 5.06, 95% CI = 1.17-21.8, p-trend = 0.04). Our data suggest that anthropometrics, breastfeeding, and alcohol intake may influence the molecular characteristics of normal breast tissue, elucidating the mechanisms by which these risk factors operate. However, larger studies

Full Text available with Trip Pro

2017 NPJ breast cancer

7. Blood Pressure Measurement as a Risk Factor for Lymphedema in Females Post Breast Cancer Treatment

Blood Pressure Measurement as a Risk Factor for Lymphedema in Females Post Breast Cancer Treatment "Blood Pressure Measurement as a Risk Factor for Lymphedema in Females " by Chelsea Braesch < > > > > > Title Author Date of Graduation Summer 8-10-2018 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Lymphedema is a common complication of breast cancer treatment. And while breast cancer survivors are at an increased risk (...) of the techniques but not the others. Conclusion: This systematic review refutes the current guidelines that patients should avoid blood pressure monitoring in the affected arm. Further research that looks at how to define lymphedema and how to best diagnose it in the clinic will help with implementing earlier treatment. Keywords: Blood pressure, lymphedema, breast cancer, and breast neoplasm Recommended Citation Braesch, Chelsea, "Blood Pressure Measurement as a Risk Factor for Lymphedema in Females Post

2018 Pacific University EBM Capstone Project

8. Breast cancer risk factors and mammographic density among high-risk women in urban China (PubMed)

Breast cancer risk factors and mammographic density among high-risk women in urban China Elevated mammographic density (MD) is an established breast cancer risk factor. Studies examining relationships between MD and breast cancer risk factors are limited in China, where established breast cancer risk factors are less prevalent but dense breasts are more prevalent than Western countries. This study included 11,478 women (45-69 years; 36% premenopausal) participating in an ongoing national cancer (...) screening program in 11 urban provinces in China and predicted as having high-risk for breast cancer. Polytomous logistic regression was performed to assess associations between MD and risk factors by comparing each higher Breast Imaging Reporting and Data System (BI-RADS) category (2, 3, or 4) to the lowest category (BI-RADS, 1). We found associations of increasing age, body mass index, weight, postmenopausal status, and parity with lower MD. Higher levels of education, increasing height, and later

Full Text available with Trip Pro

2018 NPJ breast cancer

9. The acceptability of addressing alcohol consumption as a modifiable risk factor for breast cancer: a mixed method study within breast screening services and symptomatic breast clinics. (PubMed)

The acceptability of addressing alcohol consumption as a modifiable risk factor for breast cancer: a mixed method study within breast screening services and symptomatic breast clinics. Potentially modifiable risk factors account for approximately 23% of breast cancers, with obesity and alcohol being the two greatest. Breast screening and symptomatic clinical attendances provide opportunities ('teachable moments') to link health promotion and breast cancer-prevention advice within established (...) clinical pathways. This study explored knowledge and attitudes towards alcohol as a risk factor for breast cancer, and potential challenges inherent in incorporating advice about alcohol health risks into breast clinics and screening appointments.A mixed-method study including a survey on risk factors for breast cancer and understanding of alcohol content. Survey results were explored in a series of five focus groups with women and eight semi-structured interviews with health professionals.Women

Full Text available with Trip Pro

2019 BMJ open

10. Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium (PubMed)

Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium Polygenic risk scores (PRS) for breast cancer can be used to stratify the population into groups at substantially different levels of risk. Combining PRS and environmental risk factors will improve risk prediction; however, integrating PRS into risk prediction models requires evaluation of their joint association with known environmental risk factors.Analyses (...) were based on data from 20 studies; datasets analysed ranged from 3453 to 23 104 invasive breast cancer cases and similar numbers of controls, depending on the analysed environmental risk factor. We evaluated joint associations of a 77-single nucleotide polymorphism (SNP) PRS with reproductive history, alcohol consumption, menopausal hormone therapy (MHT), height and body mass index (BMI). We tested the null hypothesis of multiplicative joint associations for PRS and each of the environmental

Full Text available with Trip Pro

2018 International journal of epidemiology

11. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer

mastectomy. [2013] [2013] 1.7 Risk reduction and treatment strategies Risk factors Risk factors 1.7.1 People should be provided with standardised written information about risk, including age as a risk factor. [2004] [2004] 1.7.2 Modifiable risk factors should be discussed on an individual basis in the relevant care setting. [2004] [2004] Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164) © NICE 2018. All (...) rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 26 of 48Menstrual and reproductiv Menstrual and reproductive factors e factors 1.7.3 Healthcare professionals should be able to provide information on the effects of hormonal and reproductive factors on breast cancer risk. [2004] [2004] Hormonal contr Hormonal contraceptiv aceptives es 1.7.4 Advice to women up to age 35 years with a family history of breast cancer should be in keeping

2013 National Institute for Health and Clinical Excellence - Clinical Guidelines

12. Persistent breast pain in post-surgery breast cancer survivors and women with no history of breast surgery or cancer: associations with pain catastrophizing, perceived breast cancer risk, breast cancer worry, and emotional distress. (PubMed)

Persistent breast pain in post-surgery breast cancer survivors and women with no history of breast surgery or cancer: associations with pain catastrophizing, perceived breast cancer risk, breast cancer worry, and emotional distress. Persistent breast pain (PBP) is prevalent among breast cancer survivors and has powerful negative psychological consequences. The present study provided a first test of the hypothesis that: (a) pain catastrophizing, (b) heightened perceived risk of cancer, and (c (...) ) worry that pain indicates cancer may be independent mediating links between breast cancer survivors' experiences of PBP and heightened emotional distress.We assessed levels of PBP and psychological factors in breast cancer survivors (Survivor Group: n = 417; Stages I-IIIA; White = 88.7%; Age M = 59.4 years) at their first surveillance mammogram post-surgery (6-15 months). A comparison group of women without histories of breast surgery or cancer (Non-cancer Group: n = 587; White = 78.7%; Age M = 57.4

Full Text available with Trip Pro

2019 Acta Oncologica

13. Risk factors for the development of brain metastases in patients with HER2-positive breast cancer (PubMed)

Risk factors for the development of brain metastases in patients with HER2-positive breast cancer Patients with metastatic human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC) frequently experience brain metastases (BM). We aimed to define risk factors for the development of BM in patients with HER2+ BC and to report on their outcome.This is a retrospective analysis of patients diagnosed with HER2+ BC between January 2000 and December 2014 at Institut Jules Bordet, Belgium (...) . Statistical analyses were conducted with SAS V.9.4 using Kaplan-Meier method and Cox regression analyses.A total of 483 patients were included of whom 108 (22.4%) developed metastases and 52 (10.8%) BM. Among 96 metastatic patients without BM at diagnosis, 40 (41.7%) developed BM in the course of their disease. In multivariate analysis, risk factors for the development of BM were age ≤40 years (HR 2.10, 95 % CI 1.02 to 4.36), tumour size >2 cm (HR 4.94, 95% CI 1.69 to 14.47), nodal involvement (HR 3.48

Full Text available with Trip Pro

2018 ESMO open

14. Chemoprevention Uptake for Breast Cancer Risk Reduction Varies by Risk Factor. (PubMed)

Chemoprevention Uptake for Breast Cancer Risk Reduction Varies by Risk Factor. The efficacy of chemoprevention for breast cancer risk reduction has been demonstrated in randomized controlled trials; however, use remains low. We sought to determine whether uptake differed by risk factors, and to identify reasons for refusal and termination.Women seen in a high-risk clinic from October 2014 to June 2017 considered eligible for chemoprevention (history of lobular carcinoma in situ, atypia, family (...) history of breast/ovarian cancer, genetic mutation, or history of chest wall radiation) were retrospectively identified. Breast cancer risk factors were compared among those with and without chemoprevention use, and compliance was noted.Overall, 1506 women were identified, 24% with prior/current chemoprevention use. Women ≥ 50 years of age were more likely to use chemoprevention than women < 50 years of age (28% vs. 11%, p < 0.001). Chemoprevention use by risk factor ranged from 7 to 40%. Having

2019 Annals of Surgical Oncology

15. Risk-reducing mastectomy for the prevention of primary breast cancer. (PubMed)

mastectomy (CRRM). Four review authors assessed the methodological quality to determine whether or not the methods used sufficiently minimized selection bias, performance bias, detection bias, and attrition bias.All 61 included studies were observational studies with some methodological limitations; randomized trials were absent. The studies presented data on 15,077 women with a wide range of risk factors for breast cancer, who underwent RRM.Twenty-one BRRM studies looking at the incidence of breast (...) Risk-reducing mastectomy for the prevention of primary breast cancer. Recent progress in understanding the genetic basis of breast cancer and widely publicized reports of celebrities undergoing risk-reducing mastectomy (RRM) have increased interest in RRM as a method of preventing breast cancer. This is an update of a Cochrane Review first published in 2004 and previously updated in 2006 and 2010.(i) To determine whether risk-reducing mastectomy reduces death rates from any cause in women who

2018 Cochrane

16. Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density (PubMed)

Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density Accurate long-term breast cancer risk assessment for women attending routine screening could help reduce the disease burden and intervention-associated harms by personalizing screening recommendations and preventive interventions.To report the accuracy of risk assessment for breast cancer during a period of 19 years.This cohort study of the Kaiser Permanente Washington breast imaging registry (...) included women without previous breast cancer, aged 40 to 73 years, who attended screening from January 1, 1996, through December 31, 2013. Follow-up was completed on December 31, 2014, and data were analyzed from March 2, 2016, through November 13, 2017.Risk factors from a questionnaire and breast density from the Breast Imaging and Reporting Data System at entry; primary risk was assessed using the Tyrer-Cuzick model.Incidence of invasive breast cancer was estimated with and without breast density

Full Text available with Trip Pro

2018 JAMA oncology

17. Risk Factors for Breast Cancer in the Breast Cancer Risk Model study of Guam and Saipan (PubMed)

Risk Factors for Breast Cancer in the Breast Cancer Risk Model study of Guam and Saipan Chamorro Pacific Islanders in the Mariana Islands have breast cancer incidence rates similar to, but mortality rates higher than, those of U.S. women. As breast cancer risk factors of women of the Mariana Islands may be unique because of ethnic and cultural differences, we studied established and suspected risk factors for breast cancer in this unstudied population.From 2010-2013, we conducted retrospective (...) case-control study of female breast cancer (104 cases and 185 controls) among women in the Mariana Islands. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for each of various lifestyle-related factors from logistic regression of breast cancer, in all women and in pre- and postmenopausal women separately. Tests for interaction of risk factors with ethnicity were based on the Wald statistics for cross-product terms.Of the medical and reproductive factors considered - age

Full Text available with Trip Pro

2017 Cancer epidemiology

18. Volumetric mammographic density, age-related decline, and breast cancer risk factors in a national breast cancer screening program. (PubMed)

Volumetric mammographic density, age-related decline, and breast cancer risk factors in a national breast cancer screening program. Background: Volumetric mammographic density (VMD) measures can be obtained automatically, but it is not clear how these relate to breast cancer risk factors.Methods: The cohort consisted of 46,428 women (ages 49-71 years) who participated in BreastScreen Norway between 2007 and 2014 and had information on VMD and breast cancer risk factors. We estimated means (...) of percent and absolute VMD associated with age, menopausal status, body mass index (BMI), and other factors.Results: The associations between VMD and most breast cancer risk factors were modest, although highly significant. BMI was positively associated with absolute VMD, whereas inversely associated with percent VMD. Percent VMD was inversely associated with a 5-year older age at screening in premenopausal and postmenopausal women (-0.18% vs. -0.08% for percent VMD and -0.11 cm3 vs. -0.03 cm3

2018 Cancer Epidemiology & Biomarkers and Prevention

19. Abemaciclib (Verzenios) For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therap

Abemaciclib (Verzenios) For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therap 1 1 SMC2179 abemaciclib 50mg, 100mg and 150mg tablets (Verzenios®) Eli Lilly and Company 5 April 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug (...) and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission assessed under the end of life process abemaciclib (Verzenios®) is accepted for restricted use within NHSScotland. Indication under review: For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with fulvestrant* as initial endocrine-based therapy

2019 Scottish Medicines Consortium

20. Palbociclib (Ibrance) - hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer

Palbociclib (Ibrance) - hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer 1 Published 8 July 2019 1 SMC2149 palbociclib 75mg, 100mg, and 125mg hard capsules (Ibrance®) Pfizer Limited 7 June 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised (...) as follows: ADVICE: following a full submission considered under the end of life and orphan equivalent assessment process. palbociclib (Ibrance ® ) is accepted for use within NHSScotland. Indication under review: for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. In pre

2019 Scottish Medicines Consortium

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>